ViiV Healthcare presented data this week showing that 69% of participants rated CAB injections as “totally or very acceptable,” compared with 48% for LEN. Additionally, 90% of participants and 86% of HCPs preferred CAB over LEN after receiving single doses of both injectables.
“Understanding differences in acceptability and tolerability is key when choosing between injectable options. These early findings help empower individuals and providers to make fully informed choices,” ViiV Healthcare Chief Medical Officer Jean van Wyk, MBChB, MFPM, said in a statement.
The results were presented at the ongoing 20th European AIDS Conference (EACS) in Paris, and underscore how injection-site reaction (ISR) experiences can shape preferences for long-acting HIV prevention and treatment options.
In a recent interview with Contagion, van Wyk, MBChB, MFPM, shared some of the company’s strategies for its long-acting injectables.